Pentadeca Arginate (PDA)

Also known as: PDA peptide

Pentadeca Arginate (PDA) is an arginate-salt analog structurally derived from the BPC-157 peptide sequence, marketed primarily for tissue repair applications. Its proposed mechanism of action is inferred from BPC-157, which is known to modulate angiogenesis, growth factor expression (e.g., VEGF, TGF-β), and nitric oxide signaling to promote wound healing, gastrointestinal protection, and tendon/ligament repair. However, as an arginate salt, PDA may exhibit altered pharmacokinetics or bioavailability compared to the parent peptide, though no independent mechanistic studies have been published to confirm or characterize these differences. Currently, PDA remains an experimental compound with no peer-reviewed research available in PubMed (0 citations). Any claims regarding its efficacy or safety are extrapolated from BPC-157 literature, which itself is primarily based on preclinical animal models. Without direct human or animal studies on PDA, its tissue-repair potential, optimal dosing, and toxicity profile remain unvalidated. Given the absence of published data, PDA has no established clinical relevance. Its use in human subjects is unsupported by evidence, and potential risks—including off-target effects or unknown interactions—cannot be assessed. For research purposes only — not medical advice.

Key data

Frequently asked questions

Related peptides